- AuthorisedPhase II and Phase III (Integrated)
An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition
This study is for children aged 3-18 with a type of brain tumour called medulloblastoma. It looks at different ways to treat the tumour, including various chemotherapy drugs, to find the most effective and safest options for different types of medulloblastoma, aiming to improve chances of recovery and quality of life.
For: MedulloblastomaSpain · Netherlands · Czechia - AuthorisedTherapeutic exploratory (Phase II)
Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening - SonoFIRST
This study looks at a new way to treat a serious type of brain cancer called glioblastoma. We're testing if sound waves can help medicines work better when given with standard treatments like chemotherapy and radiotherapy.
For: Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resectionFrance · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
EORTC 1634-BTG (NOA-23): Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)
This study looks at a new way to treat médulloblastoma, a type of brain cancer, in adults. It compares a personalised treatment to the standard one, aiming to find better ways to help patients live longer and improve their quality of life.
For: Newly Diagnosed MedulloblastomaGermany